Firstly, they compared the Gal-3 protein expression levels between MSCs derived from the BM of healthy donors and de novo patients with AML by proteomic analysis, which was higher in de novo AML patient-derived MSCs. Here, LGALS3 is linked to acute myeloid leukemia.